Fig. 8: Controlled relative vaccine efficacy curves. | Nature Communications

Fig. 8: Controlled relative vaccine efficacy curves.

From: Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost

Fig. 8: Controlled relative vaccine efficacy curves.The alternative text for this image may have been generated using AI.

The curves show the contrast in the estimated COVID-19 cumulative incidence at 188 days post-D15 for the hypothetical assignment of all participants to an Omicron-containing vaccine and the a D15 BA.1 titer or b D15 weighted average to a given fixed value with the overall estimated cumulative incidence of Prototype vaccine recipients [Stage 2 Pfizer-BioNTech vaccine arms 7 (Prototype), 8 (Beta + Omicron), 9 (Omicron), 12 (Prototype + Omicron)]. Estimation of the curve was restricted to the middle 95% of the marker distribution. Shaded regions represent 95% confidence intervals. The green shaded region is a smoothed histogram of log10 a D15 BA.1 titer (AU/ml) or b D15 weighted average titer. Analyses adjusted for the force of infection score, risk score, and baseline naïve/non-naïve status. Wt. Avg. = Maximum diversity-weighted geometric mean of the five neutralizing antibody titers D614G, Beta, Delta, BA.1, and BA.4/BA.5. AU, arbitrary units; nAb-ID50, 50% inhibitory dilution neutralizing antibody titer. Source data are provided as a Source Data file.

Back to article page